Streetbeat News

Analyst Ratings

WDAY

21 analysts have recently shared their evaluations of Workday (NASDAQ:WDAY), showing a mix of bullish to bearish sentiments. The average 12-month price target for WDAY has been raised to $289.14, up from $258.61, indicating a positive outlook. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and Workday's performance. Workday, a cloud-only software provider, has shown a revenue growth rate of 16.67% as of October 31, 2023, but faces challenges with below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 3:00 pm

ACM

AECOM (NYSE:ACM) has been evaluated by 4 analysts over the last three months, with a consensus leaning towards a somewhat bullish stance. The average 12-month price target for AECOM has been raised to $104.00, indicating a 9.47% increase from the previous target of $95.00. Analysts' actions, including raised and maintained ratings, reflect a positive outlook on AECOM's market performance. The company, a global provider of design, engineering, and construction services, reported a 15.3% revenue growth and a strong ROE of 4.24%, despite a net margin of 2.42% and a high debt-to-equity ratio of 1.21.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 3:00 pm

SMCI

In the last three months, 8 analysts have updated their ratings on Super Micro Computer (NASDAQ:SMCI), showing a diverse range of perspectives. The average 12-month price target has risen by 19.12% to $484.0, with a high estimate of $961.00 and a low of $160.00. Analysts have adjusted their ratings and price targets, reflecting a positive outlook on SMCI's performance. The company has shown remarkable revenue growth of 103.25% as of December 31, 2023, with a strong net margin of 8.08% and an ROE of 11.29%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 3:00 pm

BPMC

Blueprint Medicines (NASDAQ:BPMC) has received mixed analyst ratings over the past three months, with a shift towards a more bullish outlook in recent evaluations. The average 12-month price target for BPMC has increased to $96.83, indicating a 19.54% rise from the previous target. Analysts from firms like Barclays, JMP Securities, and Stifel have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Despite the positive analyst sentiment, Blueprint Medicines faces challenges such as a decline in revenue growth and below-average returns on equity and assets.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 3:00 pm

AFRM

AI

ALT

DAR

GD

VRT

Jim Cramer shared his views on several companies on CNBC's 'Mad Money Lightning Round,' praising Vertiv Holdings and General Dynamics for their performance and leadership, respectively. He was cautious about C3.ai due to its lack of earnings and described Altimmune as a speculative play. Cramer recommended Affirm Holdings, highlighting its strong fiscal second-quarter revenue growth. He found Darling Ingredients interesting but noted its declining stock price. Analysts have provided updates on these companies, including earnings expectations and price targets.

Portfolio Pulse from Avi Kapoor

February 13, 2024 | 2:55 pm

DIS

Walt Disney (NYSE:DIS) has seen unusual options activity, with a significant bullish sentiment among high-rolling investors, as tracked by Benzinga. The activity includes 9 options trades, with 77% bullish and 22% bearish sentiment, aiming for a price target between $110.0 and $160.0. The trading volume and open interest in DIS options have been analyzed, showing a preference for calls over puts. Disney operates in entertainment, sports, and experiences, with its current stock price at $108.52, down by -0.7%.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 2:46 pm

MARA

Marathon Digital Holdings (NASDAQ:MARA) has seen unusual options activity indicating a bearish stance by significant investors, with a sentiment split of 30% bullish and 70% bearish. The activity suggests a price target range of $22.0 to $35.0 over the next three months. The company, focusing on digital asset mining, has experienced a 10.34% decrease in stock price to $24.46. An analyst from BTIG upgraded MARA to Buy with a target price of $27. The next earnings report is due in 30 days.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 2:46 pm

ALT

Kerrisdale Capital has released a report on Altimmune, Inc. (ALT) with a critical view, titled 'Altimmune, Inc. (ALT) Fat Chance'. The report likely presents a bearish outlook on the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 2:42 pm

FANG

Scotiabank analyst Paul Cheng has maintained a Sector Outperform rating on Diamondback Energy (NASDAQ:FANG) and increased the price target from $180 to $200.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 2:40 pm

STTK

Needham analyst Gil Blum has reiterated a Buy rating on Shattuck Labs (NASDAQ:STTK) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 2:38 pm